MG
TEVA icon

Mather Group’s Teva Pharmaceuticals TEVA Stock Holding History

Mather Group’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.92K Buy
145
+135
+1,350% +$4.5K ﹤0.01% 1625
2026
Q1 		$305 Buy
+10
New +$322 ﹤0.01% 1829
2024
Q3 		– Sell
-339
Closed -$4.78K – 2165
2024
Q2 		$4.78K Buy
+339
New +$5.22K ﹤0.01% 1633

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Mather Group's TEVA Position: Q2 2026 in Review

Mather Group increased its Teva Pharmaceuticals (TEVA) stake by 1,350% in Q2 2026, buying an estimated $4.5K and bringing the position to 145 shares worth $4.92K. The position accounts for ﹤0.01% of the portfolio, ranked #1625.

Mather Group first reported a position in TEVA in Q2 2024 and has held it in 3 quarters since. 675 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Mather Group held 145 shares of Teva Pharmaceuticals worth $4.92K as of Q2 2026.
  • Mather Group bought 135 Teva Pharmaceuticals shares in Q2 2026, an estimated $4.5K.
  • Teva Pharmaceuticals made up ﹤0.01% of Mather Group's portfolio in Q2 2026, its #1625 holding.
  • Mather Group first reported a position in Teva Pharmaceuticals in Q2 2024 and has held it in 3 quarters since.
  • 675 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Mather Group's 13F filing for Q2 2026, filed 27 Jul 2026.